Scholar Rock (SRRK) Set to Release Earnings on Tuesday

Scholar Rock (NASDAQ:SRRK) is projected to release its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect Scholar Rock to post earnings of ($0.8472) per share and revenue of $0.30 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:00 AM ET.

Scholar Rock (NASDAQ:SRRK) last issued its earnings results on Thursday, August 6th. The company reported ($0.84) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.84). During the same quarter in the prior year, the business posted ($0.98) earnings per share. On average, analysts expect Scholar Rock to post ($3.29) EPS for the current fiscal year and ($2.78) EPS for the next fiscal year.

Scholar Rock Price Performance

Shares of SRRK stock opened at $46.94 on Friday. Scholar Rock has a 52-week low of $27.07 and a 52-week high of $61.76. The stock has a market cap of $5.72 billion, a PE ratio of -13.61 and a beta of 0.78. The company has a debt-to-equity ratio of 0.77, a quick ratio of 7.02 and a current ratio of 7.02. The firm’s 50 day moving average price is $47.13 and its two-hundred day moving average price is $48.19.

Insider Buying and Selling at Scholar Rock

In other news, Director Srinivas Akkaraju purchased 146,970 shares of Scholar Rock stock in a transaction dated Monday, October 26th. The shares were bought at an average cost of $41.59 per share, with a total value of $6,112,482.30. Following the completion of the transaction, the director directly owned 6,380,517 shares in the company, valued at $265,365,702.03. This trade represents a 2.36% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 10.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have commented on SRRK. JPMorgan Chase & Co. upped their target price on shares of Scholar Rock from $63.00 to $70.00 and gave the company an “overweight” rating in a research report on Monday, September 21st. Citigroup raised their price target on Scholar Rock from $60.00 to $74.00 and gave the stock a “buy” rating in a research report on Monday, September 14th. Barclays lowered Scholar Rock from an “overweight” rating to a “cautious” rating in a research report on Tuesday, September 15th. TD Cowen reaffirmed a “buy” rating on shares of Scholar Rock in a research note on Monday, September 14th. Finally, Wedbush reiterated an “outperform” rating and issued a $64.00 price objective on shares of Scholar Rock in a report on Tuesday, September 15th. Four analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $67.67.

About Scholar Rock

Scholar Rock, Inc is a biotechnology company focused on developing medicines that selectively target growth factors in the transforming growth factor beta (TGF-β) superfamily. The company’s research is intended to address serious diseases in which these signaling pathways play an important role, including neuromuscular and metabolic conditions.

Scholar Rock’s lead investigational product is apitegromab, a monoclonal antibody designed to inhibit the activation of myostatin, a protein that limits muscle growth.